Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1575)	5/30/2003 7:33:33 AM
From: Icebrg	Read Replies (1) \| Respond to of 3044

I wrote: >> Conclusion: This appears to be an interesting approach. The field is already filling up with competitors and it is questionable how far Millennium will get. They appear to have been a slow starter (the compound came with Cor).>> Or perhaps not. If there are abt. 10.000 new cases each year in the US and about 30 % of these carry the gene mutation there will not be enough patients to make the development worthwhile (from an economical perspective). And four different companies chasing the same target will not make things better. Shall we guess that this drug is purged when Millennium reviews its drug development portfolio later this year. Unless they have found another use for it. They might already have done so. The drug is not to be found on ClinicalTrials.org Erik